“A simple, non-sputum sample,” say Pai et al,53 “combined with an affordable, multi-disease POC molecular technology, deployed in decentralized settings would reach a much larger population, close the case detection gap, and curb TB transmission at the population level.” Screening for tuberculosis and latent tuberculosis have been made more feasible with the advent of interferon-gamma release assays (IGRAs), which have many advantages over tuberculin skin tests, and the C-tb skin test. The gene discussed is IFNG; the disease is tuberculosis.